Back HCV Treatment

HCV Treatment

EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5

An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more:

EASL 2015: Gilead Triple Combination Cures Easy-To-Treat Hepatitis C Patients in 6 Weeks

A 6-week regimen of sofosbuvir (Sovaldi) plus 2 experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver cirrhosis, according to a poster presentation at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. A 4-week regimen was not effective for any group, however, and 6 weeks appears inadequate for harder-to-treat patients. Other studies showed that the new drugs -- GS-5816 (velpatasvir) and GS-9857 -- are also active against other HCV genotypes.

alt

Read more:

Coverage of the 2015 EASL International Liver Congress

HIVandHepatitis.com coverage of the 50th European Association for the Study of the Liver International Liver Congress (EASL 2015) in Vienna, April 22-26, 2015.

Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV antivirals, hepatitis B and delta, and management of liver disease complications.

Full listing by topic

International Liver Congress website

5/5/15

alt

EASL 2015: Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis

Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of genotype 1 chronic hepatitis C patients with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. The sustained response rate in HCV-TARGET fell to 39% for genotype 3, but another study found that 70% of genotype 3 patients with decompensated cirrhosis could be cured with sofosbuvir plus daclatasvir (Daklinza), while sofosbuvir/ledipasvir (Harvoni) cured up to 86% of genotype 1 patients.

alt

Read more:

EASL 2015: Paritaprevir and Ombitasvir Are Effective for Japanese Patients with HCV Genotype 1b

AbbVie's paritaprevir/ritonavir/ombitasvir coformulation (Viekirax in Europe; part of the Viekira Pak regimen in the U.S.) was highly effective in curing hepatitis C without the accompaniment of dasabuvir (Exviera) in Japanese people with genotype 1b hepatitis C virus (HCV) infection in the GIFT-1 trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.

alt

Read more: